🤖 Built upon a decade-long legacy of robotic ultrasonography products, today NeuraSignal is focused on taking its FDA-cleared NovaGuide platform to market. Currently, only around 8% of hospitals that treat stroke utilize TCD, as it must be performed by a trained neurovascular sonographer. NeuraSignal CEO Robert Hamilton, PhD estimates that there are between 200 and 300 comprehensive stroke centers in the US, with primary stroke centers ranking just below them in terms of prestige, surgical capability, and revenue generation. With its NovaGuide platform, NeuraSignal aims to equip more institutions with automated TCD technology, so they may be able to detect disease states earlier than the current standard of care: https://bit.ly/3PikSSH #medtech #medicaldevices #startups #strokecare #robotics #neurology #brainhealth
